[go: up one dir, main page]

MX2019006721A - Tratamiento para la colangitis biliar primaria. - Google Patents

Tratamiento para la colangitis biliar primaria.

Info

Publication number
MX2019006721A
MX2019006721A MX2019006721A MX2019006721A MX2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A MX 2019006721 A MX2019006721 A MX 2019006721A
Authority
MX
Mexico
Prior art keywords
treatment
primary bile
cholangitis
pbc
bile cholangitis
Prior art date
Application number
MX2019006721A
Other languages
English (en)
Other versions
MX382765B (es
Inventor
Jain Mukul
Philip Binu
Patel Pankaj
Giri Suresh
V Parmar Deven
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2019006721A publication Critical patent/MX2019006721A/es
Publication of MX382765B publication Critical patent/MX382765B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención proporciona un compuesto terapéutico para la prevención y el tratamiento de la colangitis biliar primaria (PBC). De manera específica, la presente invención proporciona una composición farmacéutica que comprende un compuesto de la Formula (I) o una sal farmacéuticamente aceptable del mismo, para el tratamiento de la PBC. (Ver Fórmula).
MX2019006721A 2016-12-09 2017-12-08 Tratamiento para la colangitis biliar primaria. MX382765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621042122 2016-12-09
PCT/IB2017/057746 WO2018104916A1 (en) 2016-12-09 2017-12-08 Treatment for primary biliary cholangitis

Publications (2)

Publication Number Publication Date
MX2019006721A true MX2019006721A (es) 2019-10-30
MX382765B MX382765B (es) 2025-03-13

Family

ID=60957351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006721A MX382765B (es) 2016-12-09 2017-12-08 Tratamiento para la colangitis biliar primaria.

Country Status (8)

Country Link
US (7) US20180243263A1 (es)
EP (1) EP3551180B1 (es)
JP (1) JP6840853B2 (es)
BR (1) BR112019011740A2 (es)
ES (1) ES2894261T3 (es)
MX (1) MX382765B (es)
WO (1) WO2018104916A1 (es)
ZA (1) ZA201903649B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
EP3551180B1 (en) * 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
EP3890747A4 (en) 2018-12-05 2022-08-03 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION
WO2022040110A2 (en) * 2020-08-18 2022-02-24 Sheng Liu Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases
WO2022180612A1 (en) * 2021-02-26 2022-09-01 Cadila Healthcare Limited Orodispersible formulation of hypolipidemic agent

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
DE69615016T2 (de) 1995-04-28 2002-05-02 Daiichi Pharmaceutical Co., Ltd. Pentacyclische verbindungen
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IL150821A0 (en) 2000-01-19 2003-02-12 Cadila Healthcare Ltd Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
BR112012012815B8 (pt) 2009-11-26 2021-05-25 Genfit uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico
DE102010012223A1 (de) 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Präparat
BR112013008985A2 (pt) 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
DK2670486T3 (en) 2011-01-31 2016-05-17 Cadila Healthcare Ltd TREATMENT FOR LIPODYSTROPHY
RU2625309C2 (ru) 2011-04-22 2017-07-13 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
US20150132289A1 (en) 2012-02-29 2015-05-14 Therapix Biosciences Ltd. Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
SG11201408501UA (en) * 2012-06-19 2015-01-29 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
MY180160A (en) * 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
EP3039011A1 (en) 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (es) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
TN2017000344A1 (en) 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
CA2980296A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
US10385017B2 (en) * 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
EP3551180B1 (en) * 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis

Also Published As

Publication number Publication date
BR112019011740A2 (pt) 2019-10-29
US20230201162A1 (en) 2023-06-29
EP3551180B1 (en) 2021-09-29
US20180243263A1 (en) 2018-08-30
US12178799B2 (en) 2024-12-31
EP3551180A1 (en) 2019-10-16
ES2894261T3 (es) 2022-02-14
US20230255932A1 (en) 2023-08-17
US20250041269A1 (en) 2025-02-06
JP6840853B2 (ja) 2021-03-10
US20210085644A1 (en) 2021-03-25
MX382765B (es) 2025-03-13
JP2020502095A (ja) 2020-01-23
ZA201903649B (en) 2021-01-27
WO2018104916A1 (en) 2018-06-14
US20210128525A1 (en) 2021-05-06
US11872209B2 (en) 2024-01-16
US20220062231A1 (en) 2022-03-03
US11433050B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2019000201A (es) Compuestos inhibidores del vih
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
MX2019001581A (es) Inhibidores de ssao de aminopirimidina.
MX2017009449A (es) Inhibidor jak.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR101740A1 (es) Terapia de combinación y composiciones
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
CR20190361A (es) Dendrímeros terapéuticos
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
SV2016005313A (es) Derivados de carboxamida
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
UY36123A (es) Derivados de carboxamida
UY36331A (es) Composición farmacéutica sólida que comprende amlodipina y losartán
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
CU20160170A7 (es) Derivados de carboxamida